Launching a new category of pre-clinical research with AI-driven insights from functional human organs in 'Human Data Trials'.
Revalia Bio has raised $14.5M in total funding. The most recent round was Seed. The last funding was announced in September 2025.
Revalia Bio's investors include Sierra Ventures, Connecticut Innovations, America’s Frontier Fund, Overmatch Ventures, National Kidney Foundation.
Revalia Bio is headquartered in New Haven, United States.
Launching a new category of pre-clinical research with AI-driven insights from functional human organs in 'Human Data Trials'.
Revalia Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Revalia Bio — Funding & Investors." VCBacked, September 4, 2025, https://www.vcbacked.co/company/revalia-bio. Accessed July 20, 2026.
VCBacked. (2025). Revalia Bio — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/revalia-bio
{{cite web |title=Revalia Bio — Funding & Investors |url=https://www.vcbacked.co/company/revalia-bio |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated